Neurocrine Biosciences | NBIX - Trade Debtors


Neurocrine Biosciences reported $887M in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
ALKERMES USD 456.48M 48.85M Jun/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amgen USD 10.23B 1.09B Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Exelixis USD 322.21M 6.73M Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
Halozyme Therapeutics USD 453.33M 4.66M Jun/2026
Incyte USD 1.13B 73.7M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Pfizer USD 16.19B 19M Jun/2026
Prothena USD 5.16M 0 Dec/2023
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Repligen USD 157.71M 6.16M Jun/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Teva Pharmaceutical Industries USD 3.49B 100M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026